The high potential of LAG-3 blockade for cancer therapy is evidenced by the results in melanoma patients, who progressed despite previous immunotherapy not related to LAG-3 and who showed an 11% objective response rate when treated with relatlimab, with 1 complete and 6 partial responders (17). This evidence concerns the gene LAG3 and melanoma.